- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04023565
Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome (COMPOSER)
Open-Label Non-Comparative Study of the Effects of a Combination Antihypertensive Treatment With Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome
The aim of study is to assess the angioprotective effects of antihypertensive combination therapy with perindopril 10 mg and moxonidine 0.4-0.6 mg in patients with arterial hypertension, metabolic syndrome, and obesity, who had Pulse Wave Velocity (PWV) > 10 m/s on the previously administered two-component combination antihypertensive therapy.
Open-label non-comparative prospective study for 24 week for each patient.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
According to European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) Guidelines for the management of arterial hypertension 2018 in case of previous combination at full dose does not allow to achieve the target Blood Pressure (BP), that therapy might be switch to different two-drug combination.
The study will enroll 120 hypertensive (Grade 1, 2 Arterial Hypertension (AH): Systolic Blood Pressure (SBP) 140-179 mm Hg and Diastolic Blood Pressure (DBP) 90-109 mm Hg According to ESC/ESH Guidelines 2018) patients with metabolic syndrome who met the inclusion criteria when treated with Angiotensin Converting Enzyme Inhibition(ACEi) /Angiotensin Receptor Blocker (ARB) + hydrochlorothiazide (HCTZ)/indapamide or +amlodipine (30 patients in each group):
- ACEi (except perindopril) + diuretic (HCTZ or indapamide)
- ACEi (except perindopril) + amlodipine
- ARB+ diuretic (HCTZ or indapamide)
- ARB+ amlodipine
Upon obtaining Inform Consent the previous therapy will be discontinued according to recommendations (gradually or at once).
After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.
If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses).
FORBIDDEN TREATMENTS:
Any other antihypertensives (calcium antagonists, β-blockers, ACEi except perindopril, ARBs, diuretics) for routine AH management (except those used to resolve the uncontrolled hypertension).
CRITERIA FOR PREMATURE PATIENT WITHDRAWAL FROM THE STUDY:
- Withdrawal of informed consent by the patient at any time of the study.
- Need for uncontrolled hypertension management occurring more than 2 times weekly throughout the 2 consecutive weeks during study period.
- Need for the third antihypertensive drug.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Sergey V. Nedogoda, Professor
- Phone Number: +79023643226
- Email: nedogodasv@rambler.ru
Study Locations
-
-
-
Volgograd, Russian Federation, 400131
- Recruiting
- Dept. of Therapy and Endocrinology
-
Contact:
- Sergey V. Nedogoda, Professor
- Phone Number: +79023643226
- Email: nedogodasv@rambler.ru
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients (male and female) aging 18 to 70 years.
- Grade 1, 2 AH (SBP 140-179 mm Hg and/or DBP 90-109 mm Hg according 2018 ESH/ESC guidelines)
- PWV > 10 m/s
- Previous two-component antihypertensive therapy (ACEi/ARB+ diuretic (HCTZ or indapamide) or ACEI/ARB + amlodipine) during at least 6 months prior to the study enrollment
Metabolic syndrome diagnosed by the 2009 Russian Society of Cardiology (RSC) National Guidelines criteria
- THE MAIN SIGN: central (abdominal) obesity defined as waist circumference (WC) above 80 cm in women and above 94 cm in men.
- ADDITIONAL CRITERIA:
i. - arterial hypertension (BP ≥ 130/85 mm Hg) ii. - high triglycerides (≥ 1.7 mmol/l) iii. - decreased HDL-cholesterol (<1.0 mmol/l for men; <1.2 mmol/l for women) iv. - increased LDL-cholesterol > 3.0 mmol/l v. - fasting hyperglycaemia (fasting plasma glucose ≥ 6.1 mmol/l) vi. - impaired glucose tolerance (plasma glucose at 2 hours after glucose load from ≥7.8 to ≤11.1 mmol/l)
Metabolic syndrome is defined as presence of central obesity and two of the additional criteria.
- Body Mass Index (BMI) >30 kg/m2.
- For female patients with childbearing potential: negative pregnancy test and willingness to use reliable methods of contraception until the study treatment completion
- Voluntarily signed informed consent to participate in the study.
Exclusion Criteria:
- Contraindications for using ACEi and imidazoline receptor agonists.
- Administration of perindopril or moxonidine during 6 months before the study onset.
- Metformin therapy for prophylaxis diabetes mellitus type 2 in patients with pre-diabetes, which had been started within 6 months before the study enrollment. (If a patient receives metformin for a long time, i.e., more than 6 months, he/she can be included in the study, and metformin discontinuation is not required).
- Statin and/or fibrate therapy started within 6 months before the study enrollment. (If a patient receives statins and/or fibrates for a long time, i.e., more than 6 months, he/she can be included in the study, and discontinuation of statins and fibrates is not required).
- Current diagnosis of unstable angina, acute and subacute myocardial infarction.
- Heart failure of any functional class.
- Grade 3 AH (≥ 180/110 mm Hg).
- Sinus bradycardia (heart rate ≤50/min).
- Type 1 or 2 diabetes mellitus.
- Severe comorbidities, including mental diseases.
- Acute conditions (infections, exacerbation of chronic diseases, injuries, surgical interventions).
- Alcohol abuse.
- Pregnancy and lactation.
- Serious renal dysfunction (Estimated Glomerular Filtration Rate (eGFR) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) ≤30 ml/min/1.73 m2).
- Serious hepatic dysfunction
- Malignancies diagnosed and treated during the previous 5 years prior to study enrollment.
- Inability to understand the study and to give informed consent for participation in it.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: perindopril + moxonidine
perindopril 10 mg + moxonidine 0.4 or 0.6 mg a day (given as two divided doses).
|
After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed. If target BP is achieved after 4 weeks, the dosage will remain unchanged (perindopril 10 mg + moxonidine 0.4 mg a day (given as two divided doses). If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Pulse wave velocity (PWV)
Time Frame: baseline and 24 weeks
|
To assess the PWV after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level.
|
baseline and 24 weeks
|
Change in Central Blood Pressure (BP)
Time Frame: baseline and 24 weeks
|
To assess the central BP changes (systolic BP, aortic pulse BP) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline levels.
|
baseline and 24 weeks
|
Change in Reflected wave index
Time Frame: baseline and 24 weeks
|
To assess the reflected wave index after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level.
|
baseline and 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in carbohydrate and lipid metabolism parameters markers
Time Frame: baseline and 24 weeks
|
To assess the homeostatic model assessment - insulin resistance (HOMA-IR), and lipid metabolism (total cholesterol, triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL)) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline levels.
|
baseline and 24 weeks
|
Change in the adipokine level
Time Frame: baseline and 24 weeks
|
To assess the adipokine level (leptin) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level.
|
baseline and 24 weeks
|
Change in the Inflammatory marker level
Time Frame: baseline and 24 weeks
|
To assess the high sensible C-reactive Protein (hs-CRP) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level.
|
baseline and 24 weeks
|
Change in the renin-angiotensin-aldosterone system hyperactivation marker level
Time Frame: baseline and 24 weeks
|
To assess the renin-angiotensin-aldosterone system hyperactivation marker level (plasma aldosterone-to-renin ratio) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level
|
baseline and 24 weeks
|
Change in the sympathoadrenal system hyperactivation marker levels
Time Frame: baseline and 24 weeks
|
To assess the sympathoadrenal system hyperactivation marker levels (urine excretion adrenaline, noradrenaline, dofamine levels) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline levels.
|
baseline and 24 weeks
|
Proportion of patients achieved target BP level
Time Frame: Week 4, Week 12, Week 24
|
To assess the proportion of patients (%) achieving target BP levels <130/80 mm Hg at Week 4, Week 12, Week 24
|
Week 4, Week 12, Week 24
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sergey V. Nedogoda, Professor, Volgograd State Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Disease
- Insulin Resistance
- Hyperinsulinism
- Hypertension
- Syndrome
- Metabolic Syndrome
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Angiotensin-Converting Enzyme Inhibitors
- Perindopril
- Moxonidine
Other Study ID Numbers
- MOXOD001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
Mayo ClinicCompleted
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on perindopril + moxonidine
-
University Hospital, Basel, SwitzerlandTerminated
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Royal Perth HospitalCompletedCentral Sympathetic Nervous System DiseasesAustralia
-
Baker Heart and Diabetes InstituteUnknownObesity | OverweightAustralia
-
Aristotle University Of ThessalonikiCompletedHypertension | Obesity
-
Spyridon DeftereosCompleted
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Baker Heart and Diabetes InstituteCompleted
-
Solvay PharmaceuticalsCompleted
-
Dexa Medica GroupCompleted